Quantum BioPharma Ltd.
Quantum BioPharma Ltd. QNTM Peers
See (QNTM) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| QNTM | $20.25 | -6.77% | 58.9M | -1.53 | -$13.22 | N/A |
| ZTS | $155.95 | -0.14% | 69.4B | 28.04 | $5.56 | +1.20% |
| TAK | $15.46 | +2.38% | 48.6B | 67.17 | $0.23 | +3.81% |
| HLN | $10.37 | -0.10% | 46.8B | 24.10 | $0.43 | +1.13% |
| TEVA | $16.76 | +0.00% | 19.2B | -14.56 | -$1.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| RDY | $15.03 | -0.27% | 12.5B | 19.26 | $0.78 | +0.64% |
| NBIX | $125.69 | +0.22% | 12.4B | 42.61 | $2.95 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $8.93 | -0.89% | 10.5B | -2.81 | -$3.18 | +5.37% |
Stock Comparison
QNTM vs ZTS Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ZTS has a market cap of 69.4B. Regarding current trading prices, QNTM is priced at $20.25, while ZTS trades at $155.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ZTS's P/E ratio is 28.04. In terms of profitability, QNTM's ROE is -1.88%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, QNTM is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs TAK Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, TAK has a market cap of 48.6B. Regarding current trading prices, QNTM is priced at $20.25, while TAK trades at $15.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas TAK's P/E ratio is 67.17. In terms of profitability, QNTM's ROE is -1.88%, compared to TAK's ROE of +0.04%. Regarding short-term risk, QNTM is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs HLN Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, HLN has a market cap of 46.8B. Regarding current trading prices, QNTM is priced at $20.25, while HLN trades at $10.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas HLN's P/E ratio is 24.10. In terms of profitability, QNTM's ROE is -1.88%, compared to HLN's ROE of +0.09%. Regarding short-term risk, QNTM is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs TEVA Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, TEVA has a market cap of 19.2B. Regarding current trading prices, QNTM is priced at $20.25, while TEVA trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas TEVA's P/E ratio is -14.56. In terms of profitability, QNTM's ROE is -1.88%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, QNTM is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ITCI Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, QNTM is priced at $20.25, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ITCI's P/E ratio is -180.64. In terms of profitability, QNTM's ROE is -1.88%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, QNTM is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs RDY Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, RDY has a market cap of 12.5B. Regarding current trading prices, QNTM is priced at $20.25, while RDY trades at $15.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas RDY's P/E ratio is 19.26. In terms of profitability, QNTM's ROE is -1.88%, compared to RDY's ROE of +0.18%. Regarding short-term risk, QNTM is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs NBIX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, NBIX has a market cap of 12.4B. Regarding current trading prices, QNTM is priced at $20.25, while NBIX trades at $125.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas NBIX's P/E ratio is 42.61. In terms of profitability, QNTM's ROE is -1.88%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, QNTM is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs CTLT Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, QNTM is priced at $20.25, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas CTLT's P/E ratio is -27.84. In terms of profitability, QNTM's ROE is -1.88%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, QNTM is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs VTRS Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, VTRS has a market cap of 10.5B. Regarding current trading prices, QNTM is priced at $20.25, while VTRS trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas VTRS's P/E ratio is -2.81. In terms of profitability, QNTM's ROE is -1.88%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, QNTM is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs RGC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, RGC has a market cap of 8.4B. Regarding current trading prices, QNTM is priced at $20.25, while RGC trades at $17.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas RGC's P/E ratio is -1704.00. In terms of profitability, QNTM's ROE is -1.88%, compared to RGC's ROE of -0.25%. Regarding short-term risk, QNTM is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for QNTM.
QNTM vs ELAN Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ELAN has a market cap of 7.1B. Regarding current trading prices, QNTM is priced at $20.25, while ELAN trades at $14.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ELAN's P/E ratio is 19.05. In terms of profitability, QNTM's ROE is -1.88%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, QNTM is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs LNTH Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, LNTH has a market cap of 5.7B. Regarding current trading prices, QNTM is priced at $20.25, while LNTH trades at $81.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas LNTH's P/E ratio is 23.32. In terms of profitability, QNTM's ROE is -1.88%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, QNTM is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs AMRX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, AMRX has a market cap of 3.8B. Regarding current trading prices, QNTM is priced at $20.25, while AMRX trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas AMRX's P/E ratio is -202.25. In terms of profitability, QNTM's ROE is -1.88%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, QNTM is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs PRGO Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, PRGO has a market cap of 3.7B. Regarding current trading prices, QNTM is priced at $20.25, while PRGO trades at $26.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas PRGO's P/E ratio is -22.24. In terms of profitability, QNTM's ROE is -1.88%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, QNTM is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ALVO Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ALVO has a market cap of 2.8B. Regarding current trading prices, QNTM is priced at $20.25, while ALVO trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ALVO's P/E ratio is 24.65. In terms of profitability, QNTM's ROE is -1.88%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, QNTM is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ALVOW Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ALVOW has a market cap of 2.7B. Regarding current trading prices, QNTM is priced at $20.25, while ALVOW trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ALVOW's P/E ratio is N/A. In terms of profitability, QNTM's ROE is -1.88%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, QNTM is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs HCM Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, HCM has a market cap of 2.6B. Regarding current trading prices, QNTM is priced at $20.25, while HCM trades at $15.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas HCM's P/E ratio is 75.25. In terms of profitability, QNTM's ROE is -1.88%, compared to HCM's ROE of +0.05%. Regarding short-term risk, QNTM is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs BHC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, QNTM is priced at $20.25, while BHC trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas BHC's P/E ratio is -55.50. In terms of profitability, QNTM's ROE is -1.88%, compared to BHC's ROE of +0.05%. Regarding short-term risk, QNTM is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs DCPH Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, QNTM is priced at $20.25, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas DCPH's P/E ratio is -11.58. In terms of profitability, QNTM's ROE is -1.88%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, QNTM is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs BGM Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, BGM has a market cap of 1.9B. Regarding current trading prices, QNTM is priced at $20.25, while BGM trades at $10.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas BGM's P/E ratio is -52.95. In terms of profitability, QNTM's ROE is -1.88%, compared to BGM's ROE of -0.03%. Regarding short-term risk, QNTM is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for QNTM.
QNTM vs EMBCV Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, QNTM is priced at $20.25, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas EMBCV's P/E ratio is N/A. In terms of profitability, QNTM's ROE is -1.88%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, QNTM is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for QNTM.
QNTM vs INDV Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, INDV has a market cap of 1.8B. Regarding current trading prices, QNTM is priced at $20.25, while INDV trades at $14.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas INDV's P/E ratio is -294.80. In terms of profitability, QNTM's ROE is -1.88%, compared to INDV's ROE of -0.01%. Regarding short-term risk, QNTM is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs SUPN Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, SUPN has a market cap of 1.8B. Regarding current trading prices, QNTM is priced at $20.25, while SUPN trades at $31.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas SUPN's P/E ratio is 28.40. In terms of profitability, QNTM's ROE is -1.88%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, QNTM is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs TARO Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, QNTM is priced at $20.25, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas TARO's P/E ratio is 30.05. In terms of profitability, QNTM's ROE is -1.88%, compared to TARO's ROE of +0.02%. Regarding short-term risk, QNTM is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs EVO Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, EVO has a market cap of 1.5B. Regarding current trading prices, QNTM is priced at $20.25, while EVO trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas EVO's P/E ratio is -6.27. In terms of profitability, QNTM's ROE is -1.88%, compared to EVO's ROE of -0.22%. Regarding short-term risk, QNTM is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ANIP Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, QNTM is priced at $20.25, while ANIP trades at $65.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ANIP's P/E ratio is -55.30. In terms of profitability, QNTM's ROE is -1.88%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, QNTM is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs DVAX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, QNTM is priced at $20.25, while DVAX trades at $9.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas DVAX's P/E ratio is -19.84. In terms of profitability, QNTM's ROE is -1.88%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, QNTM is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs HROW Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, QNTM is priced at $20.25, while HROW trades at $30.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas HROW's P/E ratio is -50.07. In terms of profitability, QNTM's ROE is -1.88%, compared to HROW's ROE of -0.36%. Regarding short-term risk, QNTM is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs PCRX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, QNTM is priced at $20.25, while PCRX trades at $23.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas PCRX's P/E ratio is -10.67. In terms of profitability, QNTM's ROE is -1.88%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, QNTM is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs AMPH Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, QNTM is priced at $20.25, while AMPH trades at $22.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas AMPH's P/E ratio is 8.32. In terms of profitability, QNTM's ROE is -1.88%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, QNTM is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs PAHC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, PAHC has a market cap of 1B. Regarding current trading prices, QNTM is priced at $20.25, while PAHC trades at $25.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas PAHC's P/E ratio is 32.74. In terms of profitability, QNTM's ROE is -1.88%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, QNTM is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs COLL Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, COLL has a market cap of 950.4M. Regarding current trading prices, QNTM is priced at $20.25, while COLL trades at $29.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas COLL's P/E ratio is 24.24. In terms of profitability, QNTM's ROE is -1.88%, compared to COLL's ROE of +0.19%. Regarding short-term risk, QNTM is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs PETQ Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, QNTM is priced at $20.25, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas PETQ's P/E ratio is 83.73. In terms of profitability, QNTM's ROE is -1.88%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, QNTM is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs AVDL Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, AVDL has a market cap of 857.5M. Regarding current trading prices, QNTM is priced at $20.25, while AVDL trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas AVDL's P/E ratio is -34.04. In terms of profitability, QNTM's ROE is -1.88%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, QNTM is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs CRON Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, CRON has a market cap of 736.2M. Regarding current trading prices, QNTM is priced at $20.25, while CRON trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas CRON's P/E ratio is 13.64. In terms of profitability, QNTM's ROE is -1.88%, compared to CRON's ROE of +0.05%. Regarding short-term risk, QNTM is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs EOLS Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, EOLS has a market cap of 593.8M. Regarding current trading prices, QNTM is priced at $20.25, while EOLS trades at $9.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas EOLS's P/E ratio is -10.35. In terms of profitability, QNTM's ROE is -1.88%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, QNTM is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs BDSI Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, QNTM is priced at $20.25, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas BDSI's P/E ratio is 6.82. In terms of profitability, QNTM's ROE is -1.88%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, QNTM is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs EMBC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, EMBC has a market cap of 566.3M. Regarding current trading prices, QNTM is priced at $20.25, while EMBC trades at $9.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas EMBC's P/E ratio is 10.89. In terms of profitability, QNTM's ROE is -1.88%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, QNTM is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs SIGA Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, SIGA has a market cap of 465.8M. Regarding current trading prices, QNTM is priced at $20.25, while SIGA trades at $6.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas SIGA's P/E ratio is 9.73. In terms of profitability, QNTM's ROE is -1.88%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, QNTM is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ORGO Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ORGO has a market cap of 464.2M. Regarding current trading prices, QNTM is priced at $20.25, while ORGO trades at $3.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ORGO's P/E ratio is -22.87. In terms of profitability, QNTM's ROE is -1.88%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, QNTM is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs KMDA Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, KMDA has a market cap of 445.7M. Regarding current trading prices, QNTM is priced at $20.25, while KMDA trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas KMDA's P/E ratio is 27.68. In terms of profitability, QNTM's ROE is -1.88%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, QNTM is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs TLRY Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, TLRY has a market cap of 424.6M. Regarding current trading prices, QNTM is priced at $20.25, while TLRY trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas TLRY's P/E ratio is -0.39. In terms of profitability, QNTM's ROE is -1.88%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, QNTM is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs EBS Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, EBS has a market cap of 346.3M. Regarding current trading prices, QNTM is priced at $20.25, while EBS trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas EBS's P/E ratio is -2.47. In terms of profitability, QNTM's ROE is -1.88%, compared to EBS's ROE of -0.27%. Regarding short-term risk, QNTM is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs AQST Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, AQST has a market cap of 328.8M. Regarding current trading prices, QNTM is priced at $20.25, while AQST trades at $3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas AQST's P/E ratio is -5.71. In terms of profitability, QNTM's ROE is -1.88%, compared to AQST's ROE of +1.07%. Regarding short-term risk, QNTM is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs SNDL Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, SNDL has a market cap of 311.3M. Regarding current trading prices, QNTM is priced at $20.25, while SNDL trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas SNDL's P/E ratio is -4.03. In terms of profitability, QNTM's ROE is -1.88%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, QNTM is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ALIM Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, QNTM is priced at $20.25, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ALIM's P/E ratio is 5.28. In terms of profitability, QNTM's ROE is -1.88%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, QNTM is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs LFCR Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, LFCR has a market cap of 300.6M. Regarding current trading prices, QNTM is priced at $20.25, while LFCR trades at $8.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas LFCR's P/E ratio is -5.52. In terms of profitability, QNTM's ROE is -1.88%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, QNTM is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ZYBT Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ZYBT has a market cap of 282.9M. Regarding current trading prices, QNTM is priced at $20.25, while ZYBT trades at $5.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ZYBT's P/E ratio is 99.50. In terms of profitability, QNTM's ROE is -1.88%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, QNTM is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for QNTM.
QNTM vs LNDC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, QNTM is priced at $20.25, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas LNDC's P/E ratio is -4.04. In terms of profitability, QNTM's ROE is -1.88%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, QNTM is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs TKNO Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, TKNO has a market cap of 262.4M. Regarding current trading prices, QNTM is priced at $20.25, while TKNO trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas TKNO's P/E ratio is -10.67. In terms of profitability, QNTM's ROE is -1.88%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, QNTM is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs CGC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, CGC has a market cap of 253.4M. Regarding current trading prices, QNTM is priced at $20.25, while CGC trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas CGC's P/E ratio is -0.30. In terms of profitability, QNTM's ROE is -1.88%, compared to CGC's ROE of -1.13%. Regarding short-term risk, QNTM is more volatile compared to CGC. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ACB Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ACB has a market cap of 232.7M. Regarding current trading prices, QNTM is priced at $20.25, while ACB trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ACB's P/E ratio is 22.32. In terms of profitability, QNTM's ROE is -1.88%, compared to ACB's ROE of +0.00%. Regarding short-term risk, QNTM is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs TYHT Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, QNTM is priced at $20.25, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas TYHT's P/E ratio is -1.61. In terms of profitability, QNTM's ROE is -1.88%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, QNTM is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ESPR Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ESPR has a market cap of 195.1M. Regarding current trading prices, QNTM is priced at $20.25, while ESPR trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ESPR's P/E ratio is -1.16. In terms of profitability, QNTM's ROE is -1.88%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, QNTM is more volatile compared to ESPR. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs OGI Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, OGI has a market cap of 180.7M. Regarding current trading prices, QNTM is priced at $20.25, while OGI trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas OGI's P/E ratio is 10.38. In terms of profitability, QNTM's ROE is -1.88%, compared to OGI's ROE of +0.05%. Regarding short-term risk, QNTM is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs REPH Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, QNTM is priced at $20.25, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas REPH's P/E ratio is -8.04. In terms of profitability, QNTM's ROE is -1.88%, compared to REPH's ROE of -0.22%. Regarding short-term risk, QNTM is more volatile compared to REPH. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs DERM Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, DERM has a market cap of 167.3M. Regarding current trading prices, QNTM is priced at $20.25, while DERM trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas DERM's P/E ratio is -19.41. In terms of profitability, QNTM's ROE is -1.88%, compared to DERM's ROE of -0.52%. Regarding short-term risk, QNTM is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs BIOA Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, BIOA has a market cap of 148.1M. Regarding current trading prices, QNTM is priced at $20.25, while BIOA trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas BIOA's P/E ratio is -2.09. In terms of profitability, QNTM's ROE is -1.88%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, QNTM is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs SCTL Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, QNTM is priced at $20.25, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas SCTL's P/E ratio is -7.86. In terms of profitability, QNTM's ROE is -1.88%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, QNTM is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs IRWD Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, IRWD has a market cap of 116.1M. Regarding current trading prices, QNTM is priced at $20.25, while IRWD trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas IRWD's P/E ratio is -3.77. In terms of profitability, QNTM's ROE is -1.88%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, QNTM is more volatile compared to IRWD. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs PROC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, QNTM is priced at $20.25, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas PROC's P/E ratio is 1.53. In terms of profitability, QNTM's ROE is -1.88%, compared to PROC's ROE of -2.22%. Regarding short-term risk, QNTM is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs CRDL Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, CRDL has a market cap of 112.4M. Regarding current trading prices, QNTM is priced at $20.25, while CRDL trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas CRDL's P/E ratio is -4.00. In terms of profitability, QNTM's ROE is -1.88%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, QNTM is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs THTX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, THTX has a market cap of 108.5M. Regarding current trading prices, QNTM is priced at $20.25, while THTX trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas THTX's P/E ratio is -33.71. In terms of profitability, QNTM's ROE is -1.88%, compared to THTX's ROE of +0.16%. Regarding short-term risk, QNTM is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs OPTN Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, QNTM is priced at $20.25, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas OPTN's P/E ratio is -4.42. In terms of profitability, QNTM's ROE is -1.88%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, QNTM is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ZOM Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, QNTM is priced at $20.25, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ZOM's P/E ratio is -1.62. In terms of profitability, QNTM's ROE is -1.88%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, QNTM is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs GRVI Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, QNTM is priced at $20.25, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas GRVI's P/E ratio is 26.05. In terms of profitability, QNTM's ROE is -1.88%, compared to GRVI's ROE of -5.25%. Regarding short-term risk, QNTM is more volatile compared to GRVI. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ZYNE Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, QNTM is priced at $20.25, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, QNTM's ROE is -1.88%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, QNTM is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs INCR Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, INCR has a market cap of 69.3M. Regarding current trading prices, QNTM is priced at $20.25, while INCR trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas INCR's P/E ratio is -3.42. In terms of profitability, QNTM's ROE is -1.88%, compared to INCR's ROE of -0.07%. Regarding short-term risk, QNTM is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs SSIC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, QNTM is priced at $20.25, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas SSIC's P/E ratio is 11.93. In terms of profitability, QNTM's ROE is -1.88%, compared to SSIC's ROE of +0.03%. Regarding short-term risk, QNTM is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs VLNS Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, QNTM is priced at $20.25, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas VLNS's P/E ratio is -1.03. In terms of profitability, QNTM's ROE is -1.88%, compared to VLNS's ROE of N/A. Regarding short-term risk, QNTM is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ASRT Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ASRT has a market cap of 61.4M. Regarding current trading prices, QNTM is priced at $20.25, while ASRT trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ASRT's P/E ratio is -2.00. In terms of profitability, QNTM's ROE is -1.88%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, QNTM is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs CPIX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, CPIX has a market cap of 50.1M. Regarding current trading prices, QNTM is priced at $20.25, while CPIX trades at $3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas CPIX's P/E ratio is -13.96. In terms of profitability, QNTM's ROE is -1.88%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, QNTM is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for QNTM.
QNTM vs JUPW Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, QNTM is priced at $20.25, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas JUPW's P/E ratio is -2.41. In terms of profitability, QNTM's ROE is -1.88%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, QNTM is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for QNTM.
QNTM vs SXTC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, SXTC has a market cap of 45M. Regarding current trading prices, QNTM is priced at $20.25, while SXTC trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas SXTC's P/E ratio is 0.01. In terms of profitability, QNTM's ROE is -1.88%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, QNTM is more volatile compared to SXTC. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs QLI Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, QNTM is priced at $20.25, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas QLI's P/E ratio is -4.92. In terms of profitability, QNTM's ROE is -1.88%, compared to QLI's ROE of -0.16%. Regarding short-term risk, QNTM is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs EGRX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, EGRX has a market cap of 37.6M. Regarding current trading prices, QNTM is priced at $20.25, while EGRX trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas EGRX's P/E ratio is 3.41. In terms of profitability, QNTM's ROE is -1.88%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, QNTM is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for QNTM.
QNTM vs HEXO Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, QNTM is priced at $20.25, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas HEXO's P/E ratio is -0.26. In terms of profitability, QNTM's ROE is -1.88%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, QNTM is more volatile compared to HEXO. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs KALA Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, KALA has a market cap of 30.7M. Regarding current trading prices, QNTM is priced at $20.25, while KALA trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas KALA's P/E ratio is -0.65. In terms of profitability, QNTM's ROE is -1.88%, compared to KALA's ROE of -3.69%. Regarding short-term risk, QNTM is more volatile compared to KALA. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs RMTI Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, RMTI has a market cap of 29M. Regarding current trading prices, QNTM is priced at $20.25, while RMTI trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas RMTI's P/E ratio is -84.80. In terms of profitability, QNTM's ROE is -1.88%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, QNTM is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs SCYX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, SCYX has a market cap of 26.3M. Regarding current trading prices, QNTM is priced at $20.25, while SCYX trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas SCYX's P/E ratio is -1.20. In terms of profitability, QNTM's ROE is -1.88%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, QNTM is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs CYTH Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, QNTM is priced at $20.25, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas CYTH's P/E ratio is -0.80. In terms of profitability, QNTM's ROE is -1.88%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, QNTM is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs IXHL Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, IXHL has a market cap of 20.2M. Regarding current trading prices, QNTM is priced at $20.25, while IXHL trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas IXHL's P/E ratio is -0.18. In terms of profitability, QNTM's ROE is -1.88%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, QNTM is more volatile compared to IXHL. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs DRRX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, DRRX has a market cap of 19.7M. Regarding current trading prices, QNTM is priced at $20.25, while DRRX trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas DRRX's P/E ratio is -1.32. In terms of profitability, QNTM's ROE is -1.88%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, QNTM is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs GELS Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, GELS has a market cap of 16.3M. Regarding current trading prices, QNTM is priced at $20.25, while GELS trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas GELS's P/E ratio is -7.21. In terms of profitability, QNTM's ROE is -1.88%, compared to GELS's ROE of -0.21%. Regarding short-term risk, QNTM is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs PRPH Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, PRPH has a market cap of 16.3M. Regarding current trading prices, QNTM is priced at $20.25, while PRPH trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas PRPH's P/E ratio is -0.18. In terms of profitability, QNTM's ROE is -1.88%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, QNTM is more volatile compared to PRPH. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ACRX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, QNTM is priced at $20.25, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ACRX's P/E ratio is -0.31. In terms of profitability, QNTM's ROE is -1.88%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, QNTM is more volatile compared to ACRX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs TXMD Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, TXMD has a market cap of 13.9M. Regarding current trading prices, QNTM is priced at $20.25, while TXMD trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas TXMD's P/E ratio is -6.34. In terms of profitability, QNTM's ROE is -1.88%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, QNTM is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs AYTU Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, AYTU has a market cap of 13.5M. Regarding current trading prices, QNTM is priced at $20.25, while AYTU trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas AYTU's P/E ratio is -1.46. In terms of profitability, QNTM's ROE is -1.88%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, QNTM is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for QNTM.
QNTM vs FLGC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, FLGC has a market cap of 13.1M. Regarding current trading prices, QNTM is priced at $20.25, while FLGC trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas FLGC's P/E ratio is -0.60. In terms of profitability, QNTM's ROE is -1.88%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, QNTM is more volatile compared to FLGC. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs COSM Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, COSM has a market cap of 12.3M. Regarding current trading prices, QNTM is priced at $20.25, while COSM trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas COSM's P/E ratio is -0.39. In terms of profitability, QNTM's ROE is -1.88%, compared to COSM's ROE of -0.51%. Regarding short-term risk, QNTM is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs AGRX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, QNTM is priced at $20.25, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas AGRX's P/E ratio is -0.89. In terms of profitability, QNTM's ROE is -1.88%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, QNTM is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs TLPH Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, TLPH has a market cap of 9.7M. Regarding current trading prices, QNTM is priced at $20.25, while TLPH trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas TLPH's P/E ratio is -1.08. In terms of profitability, QNTM's ROE is -1.88%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, QNTM is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs NLTX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, QNTM is priced at $20.25, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas NLTX's P/E ratio is -0.28. In terms of profitability, QNTM's ROE is -1.88%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, QNTM is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs IMCC Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, IMCC has a market cap of 7.7M. Regarding current trading prices, QNTM is priced at $20.25, while IMCC trades at $2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas IMCC's P/E ratio is -1.80. In terms of profitability, QNTM's ROE is -1.88%, compared to IMCC's ROE of -1.52%. Regarding short-term risk, QNTM is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for QNTM.
QNTM vs YCBD Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, YCBD has a market cap of 7.6M. Regarding current trading prices, QNTM is priced at $20.25, while YCBD trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas YCBD's P/E ratio is 0.01. In terms of profitability, QNTM's ROE is -1.88%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, QNTM is more volatile compared to YCBD. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs LCI Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, QNTM is priced at $20.25, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas LCI's P/E ratio is -0.04. In terms of profitability, QNTM's ROE is -1.88%, compared to LCI's ROE of +1.66%. Regarding short-term risk, QNTM is more volatile compared to LCI. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs SBFMW Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, SBFMW has a market cap of 7.3M. Regarding current trading prices, QNTM is priced at $20.25, while SBFMW trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas SBFMW's P/E ratio is -0.10. In terms of profitability, QNTM's ROE is -1.88%, compared to SBFMW's ROE of -0.21%. Regarding short-term risk, QNTM is more volatile compared to SBFMW. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs BGXX Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, QNTM is priced at $20.25, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas BGXX's P/E ratio is -0.76. In terms of profitability, QNTM's ROE is -1.88%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, QNTM is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.
QNTM vs ADMP Comparison
QNTM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QNTM stands at 58.9M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, QNTM is priced at $20.25, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QNTM currently has a P/E ratio of -1.53, whereas ADMP's P/E ratio is -0.08. In terms of profitability, QNTM's ROE is -1.88%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, QNTM is more volatile compared to ADMP. This indicates potentially higher risk in terms of short-term price fluctuations for QNTM.